Federico Cappuzzo - Researcher Profile

Publications

5 shown

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

Mark A. Socinski , Robert M. Jotte , Federico Cappuzzo +17 more

The addition of atezolizumab to bevacizumab plus chemotherapy significantly improved progression-free survival and overall survival among patients with metastatic nonsquamous NS...

2018 New England Journal of Medicine 3592 citations

Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer

Manash Chatterjee , David C. Turner , Enriqueta Felip +20 more

2016 Annals of Oncology 157 citations

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

Naiyer A. Rizvi , Julien Mazières , David Planchard +27 more

2015 The Lancet Oncology 1406 citations

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

Edward B. Garon , Tudor‐Eliade Ciuleanu , Óscar Arrieta +23 more

2014 The Lancet 1263 citations

<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Jeffrey A. Engelman , Kreshnik Zejnullahu , Tetsuya Mitsudomi +16 more

The epidermal growth factor receptor (EGFR) kinase inhibitors gefitinib and erlotinib are effective treatments for lung cancers with EGFR activating mutations, but these tumors ...

2007 Science 4399 citations

Frequent Co-Authors

Researcher Info

h-index: 5
Publications: 5
Citations: 10,817
Institution: Azienda Unità Sanitaria Locale Della Romagna

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0002-6295-6767

Impact Metrics

h-index 5

h-index: Number of publications with at least h citations each.